An Oregon committee has abandoned a controversial proposal that would have expanded treatment options for chronic pain patients under the Oregon Health Plan, but would have forced many to reduce dosages or discontinue prescription opioids.
Association of American Medical Colleges President and CEO Darrell G. Kirch, MD, issued a statement about the Opioid Workforce Act of 2019 (H.R. 2439), which was introduced in the U.S. House of Representatives and would support new addiction medicine, addiction psychiatry, or pain management residency positions.
Sagent Pharmaceuticals, announced the voluntary nationwide recall of Lot Number M813513 of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL). This product was manufactured by Zydus (Cadila Healthcare Limited) and distributed by Sagent Pharmaceuticals, Inc. Sagent has initiated this voluntary recall of Ketorolac Tromethamine Injection, USP to the to the user level due to microbial growth detected during a routine simulation of the manufacturing process, which represents the potential introduction of microorganisms into the products.
The American Society of Clinical Oncology, the American Society of Hematology, and the National Comprehensive Cancer Network® received a letter from the Centers for Disease Control and Prevention (CDC) clarifying the CDC Guideline for Prescribing Opioids for Chronic Pain on prescribing opioids to manage pain from certain conditions.